UA103366C2 - Применение деферипрона для лечения и профилактики связанных с железом глазных расстройств - Google Patents

Применение деферипрона для лечения и профилактики связанных с железом глазных расстройств

Info

Publication number
UA103366C2
UA103366C2 UAA201110546A UAA201110546A UA103366C2 UA 103366 C2 UA103366 C2 UA 103366C2 UA A201110546 A UAA201110546 A UA A201110546A UA A201110546 A UAA201110546 A UA A201110546A UA 103366 C2 UA103366 C2 UA 103366C2
Authority
UA
Ukraine
Prior art keywords
iron
deferiprone
treatment
eye
prevention
Prior art date
Application number
UAA201110546A
Other languages
English (en)
Ukrainian (uk)
Inventor
Майкл Спіно
Джошуа Лоренс Дунаеф
Original Assignee
Майкл Спіно
Джошуа Лоренс Дунаеф
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Майкл Спіно, Джошуа Лоренс Дунаеф filed Critical Майкл Спіно
Publication of UA103366C2 publication Critical patent/UA103366C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение касается местного применения деферипрона для предупреждения или лечения связанного с железом глазного нарушения. Раскрыто применение для получения медикамента или в способе профилактики железо-индуцированного повреждения глаза субъекта. Способ включает местное введение в глаз субъекту профилактически эффективного количества деферипрона.
UAA201110546A 2009-01-26 2009-11-12 Применение деферипрона для лечения и профилактики связанных с железом глазных расстройств UA103366C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention of iron-related eye disorders

Publications (1)

Publication Number Publication Date
UA103366C2 true UA103366C2 (ru) 2013-10-10

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201110546A UA103366C2 (ru) 2009-01-26 2009-11-12 Применение деферипрона для лечения и профилактики связанных с железом глазных расстройств

Country Status (24)

Country Link
US (1) US20130023569A1 (ru)
EP (1) EP2389179A4 (ru)
JP (1) JP5604631B2 (ru)
KR (1) KR20120078667A (ru)
CN (1) CN102348456A (ru)
AP (1) AP2011005843A0 (ru)
AU (1) AU2009338093B2 (ru)
BR (1) BRPI0920492A2 (ru)
CA (1) CA2750599A1 (ru)
CL (1) CL2011001812A1 (ru)
CR (1) CR20110456A (ru)
EA (1) EA201170970A1 (ru)
IL (1) IL214291A (ru)
MA (1) MA33090B1 (ru)
MX (1) MX2011007947A (ru)
MY (1) MY161269A (ru)
NI (1) NI201100148A (ru)
NZ (1) NZ594728A (ru)
PE (1) PE20120515A1 (ru)
SG (1) SG173145A1 (ru)
TN (1) TN2011000366A1 (ru)
UA (1) UA103366C2 (ru)
WO (1) WO2010083582A1 (ru)
ZA (1) ZA201105514B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242723B1 (en) * 2015-01-09 2021-10-06 The Board of Trustees of the University of Illinois Use of hinokitiol for restoring physiology in iron-deficient organisms
MX2020004107A (es) 2017-10-25 2020-07-24 Chiesi Farm Spa Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US20040225004A1 (en) * 2003-02-06 2004-11-11 Bioresponse, Llc Combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
NZ570730A (en) 2006-02-22 2013-05-31 The use of deferiprone and methods to treat and/or prevent Friedreich ataxia resulting from intracellular mishandling of iron
KR20100110396A (ko) 2006-04-14 2010-10-12 프라나 바이오테크놀로지 리미티드 연령 관련 황반 변성（에이엠디）의 치료 방법
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
US20130023569A1 (en) 2013-01-24
CN102348456A (zh) 2012-02-08
JP5604631B2 (ja) 2014-10-08
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
EP2389179A4 (en) 2012-08-29
ZA201105514B (en) 2012-10-31
SG173145A1 (en) 2011-08-29
NZ594728A (en) 2013-03-28
JP2012515725A (ja) 2012-07-12
KR20120078667A (ko) 2012-07-10
EA201170970A1 (ru) 2012-03-30
AU2009338093B2 (en) 2014-08-28
WO2010083582A1 (en) 2010-07-29
MA33090B1 (fr) 2012-03-01
IL214291A0 (en) 2011-09-27
MX2011007947A (es) 2011-12-14
AU2009338093A1 (en) 2011-09-08
CR20110456A (es) 2012-05-31
PE20120515A1 (es) 2012-05-20
EP2389179A1 (en) 2011-11-30
CA2750599A1 (en) 2010-07-29
IL214291A (en) 2015-03-31
AP2011005843A0 (en) 2011-08-31
BRPI0920492A2 (pt) 2019-07-09
CL2011001812A1 (es) 2012-02-03
NI201100148A (es) 2012-03-06

Similar Documents

Publication Publication Date Title
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2009089494A3 (en) Pharmaceutical compositions
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2013180834A3 (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
WO2012047645A3 (en) Combination treatment for rosacea
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
WO2013098416A3 (fr) Composes anti-douleur
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
WO2014153385A3 (en) Methods of treating metabolic disorders
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
CA2866819C (en) Method for treating inflammation
WO2015061777A3 (en) Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema